Testosterone Cypionate and Anastrozole Injectable Recalled for Lack of Sterility Assurance
Vita Pharmacy (Talon Compounding Pharmacy) is recalling testosterone cypionate 200mg/anastrozole 0.25mg/mL injectable in oil due to lack of assurance of sterility. The product was distributed across the United States, Washington D.C., and Puerto Rico.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source indicates FDA Class II classification. Injectable products with lack of sterility assurance carry substantial risk of serious infection or sepsis if used by patients. Although no illnesses are reported in the source, Class II designation with a non-sterile injectable product meets the "Severe" threshold per the rubric.
Plain-English summary
Vita Pharmacy, LLC, doing business as Talon Compounding Pharmacy (located at 2950 Thousand Oaks Drive, Suite 25, San Antonio, Texas 78247), is recalling testosterone cypionate 200mg/anastrozole 0.25mg/mL in oil injectable (prescription only) due to lack of assurance of sterility.
The affected product was distributed across the United States, including Washington, D.C. and Puerto Rico. The recalled lots are T1006092021:18 (beyond-use date 12/06/2021) and T1009022021:89 (beyond-use date 03/01/2022). A total of 4 vials are affected.
Patients who have received this product should consult their healthcare provider immediately. Do not use the product. Contact Vita Pharmacy, LLC dba Talon Compounding Pharmacy at 2950 Thousand Oaks Drive, Suite 25, San Antonio, Texas 78247 or contact the FDA if you have any questions.
The recalled product
- Product
- TESTOSTERONE CYPIONATE 200MG/ANASTROZOLE 0.25MG/ML IN OIL INJECTABLE, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247
- Manufacturer
- Vita Pharmacy, LLC dba Talon Compounding Pharmacy
- Category
- Drug — Injectable / Compounded
- Hazard
- lack-of-sterility
- injectable-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: T1006092021:18 BUD: 12/06/2021
- T1009022021:89 BUD: 03/01/2022
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27